This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 18, 2013 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) ("Perrigo") and Elan Corporation, plc ("Elan") today announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately
US$8.6 billion. The transaction will create a global healthcare company with an industry-leading growth profile and the geographic scale and scope to continue building a truly differentiated business.
In connection with the acquisition, Perrigo Company and Elan have been combined under a new company incorporated in
Ireland and have adopted the global name Perrigo Company plc. Shares of Perrigo will trade on the New York Stock Exchange and the Tel Aviv Stock Exchange under the ticker symbol PRGO. The scheme of arrangement to effect Perrigo's acquisition of Elan has taken effect today, and Elan shareholders will receive the consideration to which they are entitled under the scheme of arrangement within 14 days.
Perrigo Chairman and CEO,
Joseph C. Papa stated, "We are very pleased to welcome the Elan team into the Perrigo family. The combined company establishes a diversified platform that will position Perrigo well for further expansion. When combined with the royalty stream from Tysabri
®, a blockbuster product that generated revenues of
US$1.6 billion last year, this platform will create an industry-leading global healthcare company with the balance sheet liquidity and operational structure to accelerate our growth. This strategic transaction aligns with Perrigo's acquisition strategy and our previously-stated intentions to grow our business geographically and through adjacent categories. We expect the combined companies will create tremendous value for shareholders for years to come."
Key benefits of the transaction
Establishes a differentiated platform for further expansion
Strengthens business and financial profile with highly diversified revenue streams and enhanced cash flows
Creates a combined entity with industry-leading revenue, adjusted EBITDA and earnings growth rates
Platform for International Expansion
Operating base in Ireland to serve as a business hub and gateway for expansion into international markets
Scale, resources and corporate structure to drive strategic initiatives and investments
Differentiated business model well-positioned to continue growth in core markets and to expand into other international markets
Strong Business and Financial Profile
Highly diversified revenue stream
Strong pro forma cash flows to continue to support an investment grade credit profile
Robust and sustainable growth outlook
Enhances revenue, adjusted EBITDA and earnings growth rates and expands margins
Immediately accretive to Perrigo Company's adjusted earnings per share in fiscal 2014
Meaningful synergy opportunities
Perrigo continues to expect the transaction to be more than
$0.10 accretive to Perrigo's non-GAAP earnings per share in fiscal 2014, including anticipated after-tax operational synergies, related cost reductions and tax savings greater than
$150 million. Certain of these synergies result from the elimination of redundant public company costs while optimizing back-office support and the global R&D functions. Additionally, tax savings are expected to arise from the combined company being incorporated in
Ireland with organizational, operations and capitalization structures that will enable the combined company to more efficiently manage its global cash and treasury operations. The Company has the ability to continue to invest in the growth of its businesses with strong anticipated cash flows that will allow for further ongoing deleveraging.
Additional details on the strengths of the combined companies, including revenue and earnings forecasts and updated synergy targets, will be discussed in more detail during Perrigo's second quarter earnings conference call scheduled for February 6, 2014.